Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAnesthesiologyPremera Bluecross IV anesthetics Coverage Update |…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.586

    Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.586 alerts

    Get alerted when Policy 5.01.586 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of intravenous anesthetic infusions (e.g., ketamine, lidocaine) when used to treat chronic pain conditions or psychiatric/substance use disorders for Premera Bluecross members and notifies providers about investigational determination and coding guidance.

    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational scopecoding update
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionDo not bill for IV ketamine or related visits for these indications — services are considered investigational and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    Modified criteria to clarify that IV ketamine is considered investigational in any setting or in conjunction with any other service, not just when it is either monotherapy or in conjunction with psychotherapy.

    Clarified that in addition to IV ketamine, any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are also considered investigational.

    HCPCS code J2001 was removed from the policy effective October 1, 2024.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    InvestigationalIV ketamine stance
    InvestigationalIV lidocaine stance
    100+Trials listed
    40+Trial participants
    1–2Notable RCTs
    2018Guideline year

    Coverage Criteria

    Investigational (not covered) services

    Covered when ALL of the following are met:

    Investigational - Ketamine: Intravenous infusion of ketamine for the treatment of depression, anxiety, other psychiatric symptoms or disorders, substance use disorders, and/or chronic pain is considered investigational, including in any setting or in conjunction with any other service (this includes ketamine-assisted psychotherapy).

    From Policy Coverage Criteria.

    Investigational - Associated encounters: Any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which there is intravenous infusion of ketamine are considered investigational (not covered).

    From Policy Coverage Criteria.

    Investigational - Other anesthetics: Intravenous infusion of any other anesthetics (e.g., lidocaine) for the treatment of chronic pain, including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia, is considered investigational (not covered).

    From Policy Coverage Criteria.

    Policy coverage logic and evidence synthesis

    Summary of evidence and policy stance informs coverage:

    Investigational determination for IV ketamine: IV ketamine is considered investigational for treatment of chronic pain and psychiatric or substance use disorders in any setting or in conjunction with any other service (not limited to monotherapy or with psychotherapy).

    This investigational determination also applies to any associated office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered.

    Evidence summary: Randomized trials and case series show limited, transient benefit for some psychiatric conditions (e.g., small RCTs in OCD and chronic PTSD) and for select pain conditions; however, short durability, risk of adverse events (common side effects include headache, anxiety, dissociation, nausea, and dizziness), and potential publication bias limit clinical utility. Overall evidence is insufficient to determine an improvement in net health outcome.

    Intense treatment protocols, severity of adverse events, and short treatment durability limit clinical utility.

    Regulatory and off-label note: IV lidocaine and IV ketamine for chronic pain or psychiatric disorders are off-label uses: lidocaine is FDA-approved for arrhythmias and local anesthesia; ketamine is FDA-approved for anesthesia/diagnostic procedures. Off-label status may affect coverage and documentation expectations.

    The policy designates the intravenous infusion of ketamine for treatment of depression, anxiety, other psychiatric symptoms or disorders, substance use disorders, and/or chronic pain as investigational (not covered). This investigational determination applies in any setting and in conjunction with any other service, and explicitly includes ketamine-assisted psychotherapy. The policy also states that any associated office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are considered investigational.

    IV ketamine is considered investigational in any setting and when delivered with or without other services; this includes administration during psychotherapy, clinic or office visits, or evaluation-and-management encounters. The policy history clarifies that this change expands the investigational determination to apply broadly to IV ketamine regardless of treatment context and that associated visits or sessions during which IV ketamine is given are also treated as investigational.

    For chronic pain indications, the policy concludes that IV anesthetic infusions (including ketamine and lidocaine) are investigational because randomized trials and observational studies have not demonstrated a durable benefit. Trials of IV lidocaine for postherpetic neuralgia, complex regional pain syndrome, and diabetic neuropathy failed to show lasting effects, and randomized trials of IV ketamine provide only limited, short-term relief in select studies. Concerns about intense treatment protocols, adverse events, and limited treatment durability lead to the determination that evidence is insufficient to establish a net health benefit.

    Regarding psychiatric disorders, randomized controlled trials and case series report temporary or limited benefit of IV ketamine for some conditions (for example, small trials in OCD and PTSD), but the evidence is constrained by small sample sizes, potential publication bias, unblinding/carryover issues, short durability of response, and frequent adverse effects (e.g., headache, anxiety, dissociation, nausea, dizziness). Because of these limitations, the policy finds the evidence insufficient to demonstrate an improvement in net health outcome, and IV ketamine for these psychiatric indications is considered investigational.

    Coding

    Procedure and monitoring codes referencedCPT | HCPCS
    0820TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour.
    0821TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure).
    0822TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
    96366Each additional hour (list separately in addition to code for primary procedure).
    96374Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug.
    J3490Unclassified drugs.
    Added CPT CodesCPT
    0820TCPT code added (as referenced in history).
    0821TCPT code added (as referenced in history).
    0822TCPT code added (as referenced in history).
    Removed HCPCS CodesHCPCSNot Covered
    J2001HCPCS code J2001 was removed from the policy (termed October 1, 2024).

    Provider Actions and Billing Guidance

    Prior Authorization

    Prior authorization noted but investigational services remain not payable

    Intravenous infusion services and associated monitoring/psychotherapy encounter codes are listed in the coding section but the policy states these services are investigational for the covered indications; prior authorization will not make an investigational service payable.

    • Codes referenced include 0820T, 0821T, 0822T, 96365, 96366, 96374, and J3490 per the coding section.
    • Because the policy designates IV ketamine and other IV anesthetic infusions for the listed indications as investigational, prior authorization alone does not render these services covered.
    Billing Rule

    Recent coding updates affecting authorization

    Background

    IV ketamine and IV lidocaine have been studied as courses of infusions—often using subanesthetic bolus doses followed by infusions lasting approximately 1–6 hours and administered over multiple days in some protocols—for chronic neuropathic pain, fibromyalgia, chronic headache, and treatment‑resistant depression or other psychiatric disorders. Published randomized trials and systematic reviews report some short‑term symptom improvement in certain settings, but overall treatment durability is limited and adverse events are common, raising questions about long‑term safety and net clinical benefit.

    Definitions

    Chronic daily headache definition
    DefinitionA headache disorder that occurs 15 or more days a month for at least three months; includes chronic migraine, new daily persistent headache, hemicrania continua, and chronic tension-type headache.
    Minimum frequency/duration15 or more days per month for at least three months.
    Included subtypesChronic migraine; new daily persistent headache; hemicrania continua; chronic tension-type headache.
    Neuropathic pain definition
    DefinitionPain often disproportionate to the triggering injury with features such as thermal or mechanical allodynia, dysesthesia, and/or hyperalgesia; symptoms may persist ≥6 months and involve peripheral and central sensitization mechanisms.
    Key featuresAllodynia (pain from normally nonpainful stimuli), dysesthesia (ongoing unpleasant/electrical pain sensation), hyperalgesia (exaggerated response to painful stimuli).
    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational scopecoding update
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionDo not bill for IV ketamine or related visits for these indications — services are considered investigational and may be denied.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Billing GuidanceBackgroundDefinitions

    From Regulatory Status section.

    The policy history documents that CPT codes 0820T–0822T were added and that HCPCS code J2001 was removed (termed effective October 1, 2024); providers should use the current listed CPT/HCPCS codes when submitting authorizations or claims.

    • Added CPT codes: 0820T, 0821T, 0822T (History entry 02/01/24).
    • Removed HCPCS code J2001 (History entry: Remove HCPCS code J2001 from policy; termed October 1, 2024).
    Note

    Document conventional treatment options before investigational infusions

    Conventional therapies for chronic neuropathic pain and fibromyalgia (e.g., pregabalin, non‑narcotic analgesics, low‑dose antidepressants) and techniques such as sympathetic ganglion blocks with lidocaine or test infusions to assess responsiveness are described as typical therapeutic context before investigational approaches.

    • Sympathetic ganglion blocks with lidocaine have been used to treat sympathetically maintained chronic pain conditions (e.g., CRPS).
    • Test infusion of an anesthetic has been used in treatment planning to assess individual responsiveness to oral mexiletine or oral ketamine.
    Step Therapy

    Use guideline evidence to inform stepwise ordering decisions

    Ordering should align with guideline context: the 2018 joint consensus guideline notes weak to moderate evidence for IV ketamine in select pain conditions (e.g., moderate evidence for CRPS up to 12 weeks) and generally weak or no evidence for many other pain conditions.

    • Guideline findings include moderate evidence for CRPS (improvement up to 12 weeks) and weak or no evidence for mixed neuropathic pain, fibromyalgia, headache, and spinal pain.
    • Use guideline context to inform stepwise local treatment decisions; it does not change the policy investigational determination.
    Documentation Required

    Coding documentation guidance — use listed CPT/HCPCS codes

    Code and documentation must reflect the specific infusion and monitoring services billed (use the CPT/HCPCS codes listed in the coding section for infusion, monitoring, IV push, and unclassified drugs).

    • Use 0820T–0822T for continuous in‑person monitoring and intervention during psychedelic medication therapy as applicable.
    • Use 96365 (initial up to 1 hour), 96366 (each additional hour), 96374 (IV push), and J3490 (unclassified drugs) where supported by the service provided.
    Documentation Required

    Document off‑label use and clinical rationale for IV lidocaine or ketamine

    IV lidocaine and IV ketamine for chronic pain or psychiatric disorders are off‑label uses; documentation should state the indication, rationale for off‑label use, and supporting clinical justification.

    • Regulatory status: IV lidocaine is FDA‑approved for arrhythmias and local anesthesia; IV ketamine is FDA‑approved for anesthesia/diagnostic procedures—use for chronic pain or psychiatric disorders is off‑label.
    • Include indication and rationale when documenting off‑label IV lidocaine or ketamine use in the medical record and any authorization requests.
    Denial Risk

    Investigational services may be denied

    Intravenous infusion of ketamine (including ketamine‑assisted psychotherapy and any associated visits/sessions) and intravenous infusion of other anesthetics (e.g., lidocaine) for the listed indications are designated investigational and therefore are subject to denial.

    • This investigational determination applies in any setting or in conjunction with any other service.
    • Associated encounters (office visits, psychotherapy sessions, E&M) during which IV ketamine is administered are also considered investigational.
    Denial Risk

    Associated visits/sessions billed with IV ketamine may be denied

    Claims for IV ketamine and any associated office/clinic/psychotherapy/E&M sessions during which IV ketamine is administered are considered investigational and therefore may be denied; billing for related visits may not be payable when the underlying infusion is investigational.

    • The July 2026 modification clarified that investigational status applies to IV ketamine in any setting and to any associated visits or sessions during which IV ketamine is given.
    • Submitters should expect possible denial of both infusion and concurrent visit/session claims when IV ketamine is the service performed for the investigational indications.
    Pathophysiology noteProposed mechanisms include peripheral afferent sensitization, neurogenic inflammation, sympathetic coupling, and central sensitization/functional reorganization of somatosensory, motor, and autonomic circuits.
    Fibromyalgia definition
    DefinitionA chronic state of widespread pain and tenderness associated with central sensitization, focal tender points (hyperalgesia), and biochemical alterations (e.g., NMDA receptor changes, low serotonin, elevated substance P).
    Typical treatmentsNeuropathic pain medications such as pregabalin, non-narcotic analgesics, or low-dose antidepressants are commonly used.
    Clinical featuresWidespread pain, tenderness, focal tender points often at muscle-tendon junctions, and pain on movement.
    Off-label definition
    DefinitionUse of an FDA-approved drug for an indication not included in the FDA-approved labeling (e.g., IV lidocaine or IV ketamine for chronic pain or psychiatric disorders).
    Examples from policyIV lidocaine: FDA-approved for arrhythmias and local anesthesia, but IV use for chronic pain/psychiatric disorders is off-label. IV ketamine: FDA-approved for anesthesia/diagnostic procedures; IV use for chronic pain/psychiatric disorders is off-label.
    ImplicationOff-label status may affect coverage and documentation expectations; documentation should reflect indication and rationale for off-label use.